Leerink Partnrs Has Pessimistic View of Pfizer Q3 Earnings

Pfizer Inc. (NYSE:PFE) – Equities researchers at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Pfizer in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $1.10 per share for the quarter, down from their previous forecast of $1.11. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2029 earnings at $2.36 EPS.

Other analysts have also recently issued research reports about the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.76 on Friday. The stock’s 50-day simple moving average is $26.29 and its 200-day simple moving average is $27.77. The firm has a market capitalization of $145.96 billion, a PE ratio of 34.81, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company’s revenue was up 24.7% compared to the same quarter last year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.68%. Pfizer’s dividend payout ratio is presently 232.44%.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently made changes to their positions in the stock. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the fourth quarter worth $26,000. Gladius Capital Management LP grew its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $28,000. Finally, Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the 4th quarter worth about $31,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.